ORGANOGENESIS HOLDINGS INC. Current Federal Tax Expense (Benefit)
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Current Federal Tax Expense (Benefit) of -$2.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. current federal tax expense (benefit) for fiscal 2025 was -$2.55M, a 149.80% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. current federal tax expense (benefit) for fiscal 2024 was $5.13M, a 302.12% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. current federal tax expense (benefit) for fiscal 2023 was $1.27M, a 616.29% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. current federal tax expense (benefit) for fiscal 2022 was $178.00K.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$2.55M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.13M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.27M 10-K · filed 2026-02-26 |
| 2022-12-31 | $178.00K 10-K · filed 2025-02-27 |
| 2020-12-31 | -$106.00K 10-K · filed 2023-03-01 |
| 2019-12-31 | -$105.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | -$212.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |